| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Dental Public Health Sciences (Dr. del Aguila), Neurology (Dr. Longstreth), Epidemiology (Drs. del Aguila, Longstreth, McGuire, and Koepsell), Health Services (Dr. Koepsell), Environmental Health (Dr. van Belle), and Biostatistics (Dr. van Belle), University of Washington, Seattle.
Address correspondence and reprint requests to Dr. Longstreth, Department of Neurology, Box 359775, Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104-2420; e-mail: wl{at}u.washington.edu
Background: Accurate information on prognosis of ALS is useful to patients, families, and clinicians.
Methods: In a population-based study of ALS in western Washington, the authors assembled a cohort of 180 patients with incident ALS between 1990 and 1994. Information on potential prognostic factors was collected during an in-person interview. Patients also completed the Medical Outcomes Study Short Form 36 (SF-36). Vital status through December 1999 was known for all patients.
Results: Median survival was 32 months from onset of symptoms and 19 months from diagnosis. The 5-year survival after diagnosis was 7%. Older age and female sex were strongly associated with poor survival. In multivariable Cox proportional hazards regression models, factors significantly and independently associated with a worse prognosis included older age, any bulbar features at onset, shorter time from symptom onset to diagnosis, lack of a marital partner, and residence in King County. Recursive partitioning identified age, time from symptom onset to diagnosis, and marital status as the strongest predictors of survival. Good summary scores for physical health on the SF-36, but not for mental health, were significantly associated with longer survival than poor scores.
Conclusion: These findings are consistent with other population-based studies of ALS and confirm its pernicious nature. Older age, female sex, any bulbar features at onset, short time from symptom onset to diagnosis, lack of a marital partner, and disease severity are key prognostic factors. Serial measurement of severity would likely improve predictions.
This article has been cited by other articles:
|
|
 |
|
  F. Fang, U. Valdimarsdottir, C. J. Furst, C. Hultman, K. Fall, P. Sparen, and W. Ye Suicide among patients with amyotrophic lateral sclerosis Brain, July 22, 2008; (2008) awn161v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S X Xie, M S Forman, J Farmer, P Moore, Y Wang, X Wang, C M Clark, H B Coslett, A Chatterjee, S E Arnold, et al. Factors associated with survival probability in autopsy-proven frontotemporal lobar degeneration J. Neurol. Neurosurg. Psychiatry, February 1, 2008; 79(2): 126 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zoccolella, I. L. Simone, P. Lamberti, V. Samarelli, R. Tortelli, L. Serlenga, and G. Logroscino Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis Neurology, January 15, 2008; 70(3): 222 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Zoccolella, E Beghi, G Palagano, A Fraddosio, V Guerra, V Samarelli, V Lepore, I L Simone, P Lamberti, L Serlenga, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 33 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Grossman, E. M. Wood, P. Moore, M. Neumann, L. Kwong, M. S. Forman, C. M. Clark, L. F. McCluskey, B. L. Miller, V. M.-Y. Lee, et al. TDP-43 Pathologic Lesions and Clinical Phenotype in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions Arch Neurol, October 1, 2007; 64(10): 1449 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bordet, B. Buisson, M. Michaud, C. Drouot, P. Galea, P. Delaage, N. P. Akentieva, A. S. Evers, D. F. Covey, M. A. Ostuni, et al. Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 709 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Visser, R. M. van den Berg-Vos, H. Franssen, L. H. van den Berg, J. H. Wokke, J. M. Vianney de Jong, R. Holman, R. J. de Haan, and M. de Visser Disease Course and Prognostic Factors of Progressive Muscular Atrophy Arch Neurol, April 1, 2007; 64(4): 522 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Sorenson, J. Mandrekar, B. Crum, and J. C. Stevens Effect of referral bias on assessing survival in ALS Neurology, February 20, 2007; 68(8): 600 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Beghi, A. Millul, A. Micheli, E. Vitelli, G. Logroscino, and for the SLALOM Group Incidence of ALS in Lombardy, Italy Neurology, January 9, 2007; 68(2): 141 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Czaplinski, L. J. Haverkamp, A. A. Yen, E. P. Simpson, E. C. Lai, and S. H. Appel The value of database controls in pilot or futility studies in ALS Neurology, November 28, 2006; 67(10): 1827 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Kalra, A Vitale, N R Cashman, A Genge, and D L Arnold Cerebral degeneration predicts survival in amyotrophic lateral sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2006; 77(11): 1253 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kimura, C. Fujimura, S. Ishida, H. Nakajima, D. Furutama, H. Uehara, K. Shinoda, M. Sugino, and T. Hanafusa Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS Neurology, January 24, 2006; 66(2): 265 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Meininger, B. Asselain, P. Guillet, P. N. Leigh, A. Ludolph, L. Lacomblez, W. Robberecht, and for the Pentoxifylline European Group Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial Neurology, January 10, 2006; 66(1): 88 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Weisskopf, M. L. McCullough, N. Morozova, E. E. Calle, M. J. Thun, and A. Ascherio Prospective Study of Occupation and Amyotrophic Lateral Sclerosis Mortality Am. J. Epidemiol., December 15, 2005; 162(12): 1146 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P J Shaw Molecular and cellular pathways of neurodegeneration in motor neurone disease J. Neurol. Neurosurg. Psychiatry, August 1, 2005; 76(8): 1046 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Weisskopf, E. J. O'Reilly, M. L. McCullough, E. E. Calle, M. J. Thun, M. Cudkowicz, and A. Ascherio Prospective study of military service and mortality from ALS Neurology, January 11, 2005; 64(1): 32 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Weisskopf, M. L. McCullough, E. E. Calle, M. J. Thun, M. Cudkowicz, and A. Ascherio Prospective Study of Cigarette Smoking and Amyotrophic Lateral Sclerosis Am. J. Epidemiol., July 1, 2004; 160(1): 26 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chio, R. Mutani, G. Mora, W.T. Longstreth Jr., and M.A. del Aguila Prognosis in amyotrophic lateral sclerosis: A population-based study Neurology, December 23, 2003; 61(12): 1826 - 1827. [Full Text] [PDF]
|
|
|
|
 |
|
 OTHER ARTICLES NOTED (24 Jan 03 to 18 Apr 03) Evid. Based Nurs., July 1, 2003; 6(3): e1 - 12. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
